I forgot that there are other possible outcomes.

Let’s recall that 208 was more effective with Rosuvastatin than Atorvastatin in plaque reduction. The MACE numbers were there for the combined group but one there seems to be synergy between 208 and Rosuvastatin.

So, the top line could miss but the Rosuvastatin/208 group may have significantly less MACE events than the Rosuvastatin/208 group. 

With such findings, the FDA may an NDA for 208 in combination with Rosuvastatin. As of March, 2017, Resverlogix holds the patent in the US for the use of Apabetalone in combination with Rosuvastatin.

Can you say “combo pill”?

bfw